36 results about "Middle East respiratory syndrome coronavirus" patented technology

The invention discloses a subunit coronavirus vaccine for dimerization-based receptor binding domains and belongs to the technical field of medicine. A baculovirus expresses RBD (receptor binding domain (E367-Y606) of MERS-CoV (middle east respiratory syndrome coronavirus) protein and RBD (R294-F515) of SARS-CoV (severe acute respiratory syndrome coronavirus) in insect cells, the RBDs may form a dimer through cysteine residue at 603 of S (spike) protein or form a dimer through cysteine residue at 512 of the S protein, and purified RBD protein dimer and monomer are used respectively to immunize Bald / c mice. The dimerized RBDs have the advantages that the defect that RBD monomers have poor immunogenicity is overcome and the generation of neutralizing antibodies in against MERS-CoV is increased greatly.

The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.

The invention discloses a primer probe set, kit and detection method for detecting SARS-CoV and MERS-CoV based on Recombinase Polymerase Amplification (RPA) detection. The primer probe set for detecting SARS-CoV and MERS-CoV based on the RPA detection comprises primers for nucleotide sequences as shown in SEQ ID NO.1-4 and probes for nucleotide sequences as shown in SEQ ID NO. 5-6. The invention further provides the kit for detecting SARS-CoV and MERS-CoV based on the RPA detection, wherein the kit comprises the primer probe set. By adopting the technical scheme, the sensitivity, specificity and simplicity for detecting SARS-CoV and MERS-CoV are obviously improved.

The invention provides a fluorescent RT-RAA (Reverse Transcription Recombinase Aid Amplification) primer for detecting MERS-CoV (Middle East Respiratory Syndrome Coronavirus), a fluorescent probe andapplication of the fluorescent RT-RAA primer and the fluorescent probe in detecting the MERS-CoV. The fluorescent RT-RAA primer and the fluorescent probe, disclosed by the invention, are capable of quickly and qualitatively detecting the MERS-CoV in a throat swab sample, detection can be carried out under the normal temperature of 39 DEG C, a diagnosis result can be obtained within 20 minutes, andthe detection time is greatly shortened; the fluorescent RT-RAA primer and the fluorescent probe are stronger in specificity and higher in sensitivity, quick diagnosis and whole-process monitoring onan epidemic situation can be completely met, and time is bought for early diagnosing and early treating the epidemic situation, reducing a case fatality rate and controlling the epidemic situation.

The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.

The invention discloses application of a medicine which contains arbidol as a main component, and a pharmaceutically acceptable salt of the arbidol in preventing and treating anti-Middle East respiratory syndrome coronavirus. The invention discloses for the first time that arbidol hydrochloride has an anti-virus function on Middle East respiratory viruses, can prevent Middle East respiratory syndrome coronavirus from infecting host cells, and can be adopted to treat Middle East respiratory syndrome coronavirus infection.

The invention relates to the field of biomedicine, in particular to application of MERS-CoV 3CLpro (Middle East respiratory syndrome coronavirus 3C-like protease) as a deubiquitinating enzyme and interferon inhibitor. The invention provides a novel deubiquitinating enzyme and interferon inhibitor; the new understanding of the functionality of human coronavirus proteinase can be expanded; theoretical basis can be provided for the research on coronavirus and host antiviral natural immunization and the research on antiviral drugs using viral proteinase as a target.

Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against Zika virus, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), Chikungunya virus, Venezuelan equine encephalitis, and rhinovirus-14 are disclosed.

A peptide that binds to the Si spike protein of Middle East Respiratory syndrome coronavirus or MERS-CoV and a method for inhibiting infection of a subject exposed to or having MERS-CoV by administering the peptide.

Disclosed herein are nanoparticles containing MERS virus proteins in polymer structures, and compositions containing the nanoparticles formulated for administration as immunogenic compositions. Also provided herein are vector constructs encoding the proteins, and host cells containing the vector constructs. The disclosure also includes methods of making the nanoparticles and administering them to vertebrates, including methods of inducing immune responses to MERS that reduce or prevent infection by the virus.

The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.

Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.

The invention relates to a kit for gene detection of MERS-CoV, in particular to a method for simultaneously detecting UPE and N genes of MERS-CoV by using multiple real-time fluorescent polymerase chain reaction techniques. This kit mainly includes RT-PCR reaction solution, primer-probe mixture, RT-PCR reaction enzyme system, DEPC H 2 O and boxes that separate and collectively pack these reagent bottles or tubes. Since the kit uses multiple fluorescent channels to detect separately and applies a one-step real-time fluorescent PCR reaction mode, it can accurately and quickly detect the UPE and N genes of MERS-CoV, and can be widely used in clinical early diagnosis of MERS-CoV, Epidemic prevention and control, and scientific research and other fields.

The invention relates to a detection kit for an ORF1a2 gene of Middle East respiratory syndrome coronavirus, and a loop-mediated isothermal amplification-based detection method for the Middle East respiratory syndrome coronavirus. The detection method is used for performing nucleic acid detection on the ORF1a2 gene of the Middle East respiratory syndrome coronavirus in a sample on the basis of the loop-mediated isothermal amplification principle; by using specific primers and utilizing a loop-mediated isothermal amplification platform to amplifying the target gene ORF1a2, under the assistance of a positive quality control and negative control and inner control detection system, screening or detection is performed on the Middle East respiratory syndrome coronavirus in the sample from a molecular level. The method disclosed by the invention has the characteristics of being simple, economic, rapid, sensitive and specific, is capable of overcoming the defects that the time and energy are wasted and the cost is high in the prior art, and has a wide application prospect.

Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.

The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.

The invention discloses a subunit coronavirus vaccine for dimerization-based receptor binding domains and belongs to the technical field of medicine. A baculovirus expresses RBD (receptor binding domain (E367-Y606) of MERS-CoV (middle east respiratory syndrome coronavirus) protein and RBD (R294-F515) of SARS-CoV (severe acute respiratory syndrome coronavirus) in insect cells, the RBDs may form a dimer through cysteine residue at 603 of S (spike) protein or form a dimer through cysteine residue at 512 of the S protein, and purified RBD protein dimer and monomer are used respectively to immunize Bald / c mice. The dimerized RBDs have the advantages that the defect that RBD monomers have poor immunogenicity is overcome and the generation of neutralizing antibodies in against MERS-CoV is increased greatly.

The present invention belongs to the technical field of biology, and relates to a de-fucosylated fully humanized monoclonal antibody for Middle East Respiratory Syndrome Coronavirus (MERS-CoV), an antigen binding fragment, and applications thereof, wherein the de-fucosylated fully humanized monoclonal antibody is mainly characterized in that the de-fucosylated fully humanized monoclonal antibody has an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) effect, wherein the effect comprises cleaving the cells expressing MERS-CoV S protein. The present invention further relates to a method for making cells express the de-fucosylated MERS-CoV fully humanized monoclonal antibody by inhibiting fucosyltransferase activity. According to the present invention, by using the antibody, the Middle Eastern respiratory syndrome can be clinically prevented or treated.

Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.

The invention relates to application of teicoplanin in preparation of drugs for MERS-CoV (Middle East respiratory syndrome coronavirus). According to the application, teicoplanin compounds have the effect of treating the MERS-CoV in vitro.

The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and / or treating an MERS-CoV virus infection in a subject using said composition and method of generation.

The invention relates to application of glucocorticoid in preparation of a medicine for treating and / or preventing respiratory virus infection. The respiratory viruses are selected from SARS-CoV virus, SARS-CoV-2 virus, Middle East respiratory syndrome coronavirus, influenza virus, measles virus, parotitis virus, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, Hendea virus, Nipie virus, rubella virus, rhinovirus, adenovirus, reovirus, coxsackie virus and ECHO virus.

The invention provides a 4-(benzothiazole-2-yl)-N-substituted aniline compound and a preparation method thereof. The method comprises the steps of: reacting substituted 4-(benzothiazole-2-yl) aniline with a halide to generate the 4-(benzothiazole-2-yl)-N-substituted aniline compound, or reacting substituted 4-(benzothiazole-2-yl) aniline with halogenated acyl chloride, and carrying out nucleophilic substitution, reduction and nucleophilic substitution reactions to generate a series of 4-(benzothiazole-2-yl)-N-heterocyclic alkyl substituted aniline compounds. The invention also provides an application of the 4-(benzothiazole-2-yl)-N-substituted aniline compound in resisting middle east respiratory syndrome coronavirus (MERS-CoV) and novel coronavirus (SARS-CoV-2). The 4-(benzothiazole-2-yl)-N-substituted aniline compound has an application prospect in the field of discovery of new drugs for inhibiting the coronavirus.

A peptide that binds to the Si spike protein of Middle East Respiratory syndrome coronavirus or MERS-CoV and a method for inhibiting infection of a subject exposed to or having MERS-CoV by administering the peptide.

The invention provides a multiple detection kit for human coronavirus nucleic acid. Specifically, the present invention simultaneously detects human coronaviruses OC43, 229E, HKU1, NL63, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) and The nucleic acid RNA of the seven coronaviruses of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can realize rapid detection and analysis of human coronavirus nucleic acid from various sample sources.

The invention relates to the technical field of biology and discloses a single-domain heavy-chain antibody, an encoding gene, a preparation method and use thereof and a pharmaceutical composition. The single-domain heavy-chain antibody can be specifically combined with a receptor binding region of the Middle East Respiratory Syndrome Coronavirus, has good neutralizing activity on the Middle East Respiratory Syndrome Coronavirus, and has the potential as an active component in an antiviral product for preventing and treating the Middle East Respiratory Syndrome.

The invention relates to application of teicoplanin in preparation of drugs for MERS-CoV (Middle East respiratory syndrome coronavirus). According to the application, teicoplanin compounds have the effect of treating the MERS-CoV in vitro.

The invention discloses a RBD (receptor binding domain) segment in a MERS-CoV (Middle East respiratory syndrome coronavirus) membrane protein and a coding gene and application thereof. 1, A protein is as follows: (a) a protein comprising 4th to 243th-site amino acid residues from N terminal of a sequence 1 in a sequence table; or (b) a protein comprising 1th to 243th-site amino acid residues from the N terminal of the sequence 1 in the sequence table; or (c) a protein comprising 4 to 249-site amino acid residues from the N terminal of the sequence 1 in the sequence table; or (d) a protein shown as the sequence 1 of the sequence table. The invention finds that MERS-CoV may have a potential receptor binding domain (Receptor Binding Domain, RBD), and in-depth studies on the RBD help to discover a key target blocking the MERS-CoV invasion, and have important theory reference values to research and development of treatment drugs and preventive vaccines of the MERS-CoV.